CD38 expression (target of daratumumab / isatuximab)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CD38-EXPRESSION |
|---|---|
| Type | Biomarker |
| Aliases | CD38 expressionЕкспресія CD38 (мішень даратумумабу / ізатуксимабу) |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ALCYONE-MATEOS-2018 SRC-CASTOR-PALUMBO-2016 SRC-NCCN-MM-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodFlow cytometry on CD138-gated plasma cells (MM) OR IHC on BM core biopsy Unitscategorical (positive | negative); semi-quantitative MFI / % |
| Related biomarkers | None declared |
Notes
CD38 is universally expressed at high density on malignant plasma cells in multiple myeloma — basis for the entire anti-CD38 mAb class (daratumumab, isatuximab) which is now part of standard 1L MM regimens (Dara-VRd / Dara-RVd, Dara-VMP for transplant-ineligible). Cross-disease relevance + quantitative line stratification: - **MM (1L)**: assumed CD38+ on histology (plasma-cell neoplasm). Pivotal trials (ALCYONE Dara-VMP vs VMP, MAIA Dara-Rd vs Rd, GRIFFIN Dara-VRd) established anti-CD38 mAb as 1L standard. Formal IHC/flow not gating but documented at diagnosis. - **MM (R/R after anti-CD38)**: CD38 antigen loss / down-modulation is a known resistance mechanism after daratumumab — quantitative IHC / flow MFI on relapse biopsy informs class switch (BCMA-directed, selinexor, anti-SLAMF7 elotuzumab) vs anti-CD38 retreatment with isatuximab (CASTOR + IKEMA, ICARIA-MM in R/R). - **AL amyloidosis**: CD38+ on plasma-cell clone — Dara-CyBorD is standard 1L (ANDROMEDA). - **Indolent NHL / CLL**: CD38+ subset in CLL is an adverse prognostic marker (independent of BTKi-era; flag-only). - **T-ALL / NK-cell neoplasms**: CD38+ subset; daratumumab investigated in early-phase trials. Antigen-densit...
Used By
No reverse references found in the YAML corpus.